Abivax

Abivax, created by Truffle Capital, is a clinical-stage company that leverages its antiviral and immune platforms to optimize its drug candidates to cure HIV and treat inflammatory diseases, as well as cancer.

In May and June 2021, phase IIb and IIa clinical trials of ABX464 for the treatment of ulcerative colitis and rheumatoid arthritis were successfully completed. The phase III clinical trial, last step before commercialisation, is expected in 2022 for ABX464 in the treatment of ulcerative colitis.

See website

Synoptical view

Stock: Abivax is listed on EURONEXT GROWTH PARIS since june 2015

Truffle investment: € 32M

Management team

Board of Directors

President Emmanuel Macron congratulates Carbios on the 2nd anniversary of France 2030, Vexim (MedTech acquired by Stricker for $200 million), Carmat, Symetis (MedTech acquired by Boston Scientific for $430 million), Affluent Medical (MedTech, listed on the stock exchange), Diaccurate and Caranx Medical.

As a former Paris hospital intern in immunology and hematology, Dr Pouletty holds a doctorate in medicine from the University of Paris VI and a master's degree in immunology and virology from the Institut Pasteur. He was a post-doctoral researcher (1986-1988) at Stanford University.

He is the winner of the 1999 American Liver Foundation Award. Doctor Philippe Pouletty is a Chevalier de la Légion d'Honneur.

Philippe Pouletty, M.D.

Chairman of Abivax, Co-Founder & CEO at Truffle Capital

Partners

In summary

Truffle Capital has created and invested in Abivax to develop two unique platforms that address huge medical needs and a multi-billion dollar market: viral diseases, particularly HIV/AIDS, inflammatory diseases, including digestive system diseases and liver cancer.

They talk about it

We are now moving forward as quickly as possible with our phase 3 plan in ulcerative colitis as well as phase 2b/3 in Crohn’s disease to bring ABX464 to the many patients suffering from inflammatory bowel disease